Ginkgo Bioworks Holdings Inc. (DNA) stock plummeted 5.05% in pre-market trading on Thursday after reporting disappointing 2024 full-year earnings results.
The biotech company reported a net loss of $547 million for the fiscal year 2024, although this represented a 39% narrowing from the previous year. However, revenue declined by 9.7% year-over-year to $227 million, missing analyst expectations.
Looking ahead, Ginkgo Bioworks projected an average revenue decline of 2.5% per year over the next three years, underperforming the expected 4.4% growth for the broader US chemicals industry. The company's shares have fallen 28% over the past week, reflecting investors' concerns about its financial performance and growth prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。